Nivolumab boosts survival in relapsed malignant mesothelioma

Reuters Health - 02/02/2021 - Treatment with the programmed death-1 (PD-1) inhibitor nivolumab significantly improved overall and progression-free survival in patients with relapsed malignant mesothelioma in the CONFIRM study. It marks the first time a phase-3 study has demonstrated improved survival in the setting of relapsed malignant mesothelioma, said Dr. Dean Fennell of University of Leicester, in the U.K., in a presentation of the results at the International Association for the Study of Lung Cancer (IASLC) virtual World Conference on Lung Cancer (WCLC). "Nivolumab is a safe and effective treatment and should be considered the standard treatment for patients with relapsed mesothelioma," he told a gathering of reporters. The CONFIRM trial enrolled 332 adults with previously treated, unresectable malignant mesothelioma and Eastern Cooperative Oncology Group performance status of zero to one. Patients were stratified by epithelioid and non-epithelioid hist...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 2 February, 202116 February, 2021